Kristin Meliambro
Associate Professor · Icahn School of Medicine at Mount Sinai
Credentials: · · · ·
History
- 2009–2012
Internal Medicine
Research
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
New England Journal of Medicine · 2021 · 427 citations
Podocyte-Specific Deletion of Yes-Associated Protein Causes FSGS and Progressive Renal Failure
Journal of the American Society of Nephrology · 2016 · 99 citations
Association of Vaccination with the Persistence of Post-COVID Symptoms
Journal of General Internal Medicine · 2022 · 72 citations
28 papers
11 papers
- JW
10 papers
7 papers
6 papers · 1 as a fellow
5 papers
- JR
5 papers · 4 as a resident
- DM
4 papers
Grants
- 2024–2029
KIBRA-Induced Biomechanical Changes and Therapeutic Targeting in Podocytes
National Institute of Diabetes and Digestive and Kidney Diseases · R01
Contact PI · $1.6M · Icahn School of Medicine at Mount Sinai
- 2022–2027
Mount Sinai Health System Kidney Precision Medicine Project
National Institute of Diabetes and Digestive and Kidney Diseases · U01
PI · $1.1M · Icahn School of Medicine at Mount Sinai
- 2018–2023
The Role of KIBRA Signaling in Podocyte Injury
National Institute of Diabetes and Digestive and Kidney Diseases · K08
Contact PI · $896K · Icahn School of Medicine at Mount Sinai
Clinical trials
- 2025–2031
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
- 2019–2027
- 2023–2027
AMPK-activation by Metformin in FSGS: AMP-FSGS
Sub-investigator · Recruiting · Phase 1, Phase 2
Yale University